Tilray (NASDAQ:TLRY - Get Free Report) released its earnings results on Friday. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.03) by ($0.07), Zacks reports. The company had revenue of $210.90 million for the quarter, compared to the consensus estimate of $216.34 million. Tilray had a negative net margin of 26.79% and a negative return on equity of 2.00%. Tilray's quarterly revenue was up 8.7% on a year-over-year basis. Tilray updated its FY 2025 guidance to EPS.
Tilray Stock Down 10.2 %
Shares of TLRY traded down $0.14 during mid-day trading on Friday, hitting $1.23. The company's stock had a trading volume of 60,637,356 shares, compared to its average volume of 51,439,223. The company has a current ratio of 2.47, a quick ratio of 1.57 and a debt-to-equity ratio of 0.08. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -4.56 and a beta of 2.08. The company's 50-day moving average is $1.37 and its 200-day moving average is $1.62. Tilray has a 52-week low of $1.14 and a 52-week high of $2.97.
Insider Activity
In other Tilray news, CFO Carl A. Merton purchased 26,000 shares of the business's stock in a transaction that occurred on Friday, November 15th. The shares were bought at an average price of $1.36 per share, for a total transaction of $35,360.00. Following the acquisition, the chief financial officer now owns 26,000 shares in the company, valued at $35,360. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.87% of the company's stock.
Wall Street Analyst Weigh In
Separately, Roth Mkm dropped their price objective on Tilray from $2.00 to $1.75 and set a "neutral" rating for the company in a report on Friday, October 11th.
Get Our Latest Stock Report on Tilray
About Tilray
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Recommended Stories
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
